Grey's Anatomy lab coats and custom embroidery at Scrubs Unlimited

Scrubs in Los Angeles

"The lab coats, Grey's Anatomy scrubs, they are all superior quality and fit. If they were not, the people who depend on the uniforms would not buy them,"

LOS ANGELES, CA, US, February 5, 2019 /EINPresswire.com/ — Grey's Anatomy lab coats with custom embroidery are now available at Scrubs Unlimited.

Grey's Anatomy, based on the hit TV show of the same name, have built a reputation in the medical industry for wearability and durability. This is not just about the name associated with a TV show, it is about quality, said Philip Gabriel, owner of Scrubs Unlimited.

"The lab coats, Grey's Anatomy scrubs, they are all superior quality and fit. If they were not, the people who depend on the uniforms would not buy them," he said.

In addition to the great prices on Grey's Anatomy uniforms, Scrubs Unlimited offers custom embroidery. The company offers a variety of colors and fonts for all uniforms. The custom monogramming takes 10-15 days on standard orders. Rush orders are available.

"Before you order and request the embroidery, we recommend you order one set of scrubs or a Grey's Anatomy lab coat to check the size. If it fits, the place the rest of your order. If it does not fit, send it back and we cover the return shipping," Mr. Gabriel said. "This return guarantee does not apply if the item is already monogrammed."

If the size is correct, then place the order. If the size is not correct, send it back and adjust the size for the next order.

"We do recommend shipping it back via FedEx or UPS," Mr. Gabriel said. "The Post Office has lost too many shipments. You don't have to worry about the cost because we will reimburse you for that."

Companies that need to order uniforms in bulk should call (866) 267-3079 as Scrubs Unlimited can offer discounts on large orders.

Scrubs Unlimited also sells Barco uniforms with the same options for custom embroidery.

Scrubs Unlimited offers free shipping on any orders over $100.

For more information, visit <a href= "http://www.scrubsunlimited.com">Scrubs Unlimited</a>.

Philip Gabriel
Scrubs Unlimited
+1 310-208-7669
email us here

Grey’s Anatomy Lab Coats


Source: EIN Presswire

Hear from Sanofi and Merck at SMi’s Injectable Drug Delivery 2019

Hear from Sanofi as they will be presenting the Keynote Address

LONDON, UNITED KINGDOM, February 4, 2019 /EINPresswire.com/ — Hear from Sanofi as they will be presenting the Keynote Address: Overcoming the challenges in development of injectable protein formulations on day one by Vasco Filipe, Senior research scientist – Formulation Development at the 2nd annual Injectable Drug Delivery conference taking place on the 15-16 May 2019, in London, UK.

Below is a summary of Vasco Filipe presentation:
Opening Keynote Address: Overcoming the challenges in development of injectable protein formulations – Day 1 | 09:10
– High viscosity that exceeds the capabilities of current manufacturing practices or available parenteral delivery methods
– High concentration leading to stability and aggregation concerns and the associated material required for a robust development strategy
– High volume biologic challenges and strategies to overcome them
– Viscosity reducing excipients

Vasco Filipe is a Biological Engineer and obtained a Ph.D. degree in Pharmaceutical Sciences from the Utrecht University (The Netherlands) in 2011. His thesis focused on the physicochemical characteristics, stability in biological fluids and immunogenicity of monoclonal antibody aggregates. After a post-doc in 2012 on a similar topic, he then joined Adocia in 2013 (Lyon, France), where he worked as the Project Leader for all monoclonal antibodies’ collaborations. In 2015 he joined Sanofi (Paris, France), where he now works as a Section Head of Formulation and Process Development in the department of Biologics Drug Product Development.
———————————-
Quentin Le Masne, Head of Engineering team – Electro-Medical, Drug Delivery Devices, Merck will be presenting on: Development of electronic auto-injectors – from concept to manufacture on day two at 11.00am
Below is a summary of Quentin Le Masne presentation:
– Overview of the development process – the do’s and don’ts
– The challenges and learnings of electronic and connected drug delivery devices
– User experience and patient-centric design: what do patients really want from electronic auto-injectors?

Quentin Le Masne holds a master’s degree in Engineering for Ecole Centrale de Paris and a PhD in Physics from Paris University. He has worked in numerous positions in the field of medical devices, from In-Vitro Diagnostic to Drug Delivery Devices, restlessly bringing highly innovative ideas from lab to market. His work focuses on the management of engineering teams with diverse expertise like electronic, mechanics, human factors, physics, fluidics, and manufacturing to bring new products in the doctor’s and patient’s hands. He is now in charge of the development of novel electronic drug delivery devices for Merck.

For those looking to attend there is currently a £300 early-bird saving, ending February 28th.
Further information is available at: www.injectable-drug-delivery.com/einpr3

SMi presents the 2nd Annual Conference:
Injectable Drug Delivery
Date: 165h – 16th May 2019
Workshops: 14th May 21019
Location: Copthorne Tara Hotel Kensington, London
Website: www.injectable-drug-delivery.com/einpr3

—ENDS—

Contact Information:
For all media inquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6048 / Email: hsidhu@smi-online.co.uk

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu
SMi Group
+1 207-827-6088
email us here


Source: EIN Presswire

ANCON Supports World Cancer Day Campaign #IAmandIWill

World Cancer Day February 4th

World Cancer Day February 4th

Wesley Baker - CEO ANCON Medical

Wesley Baker – CEO ANCON Medical

Support World Cancer Day This Year

Support World Cancer Day This Year

9.6 million people die each year from cancer. More than HIV/AIDS, malaria and tuberculosis combined. 2030, experts project cancer deaths to rise to 13 million.

Ancon Medical’s NBT device is a much better alternative than CT scans early on and far cheaper too”

— Wesley Baker – CEO of ANCON Medical

BLOOMINGTON, MINNESOTA, USA, February 3, 2019 /EINPresswire.com/ — 9.6 million people die each year from cancer. That’s more than HIV/AIDS, malaria and tuberculosis combined. By 2030, experts project cancer deaths to rise to 13 million.

World Cancer Day this 4th February marks the launch of the 3-year #IAmandIWill campaign, urging for personal commitment to increasing the power of individual action on impacting the future of cancer prevention and treatment.

A campaign built to resonate, inspire change and mobilise action, ANCON’s support of World Cancer Day offers a chance to create long-lasting impact by increasing public-facing exposure and engagement, leading to impact-driven action.

Designed specifically with the goals of early diagnosis and differentiation of cancer in mind, ANCON Medical’s Nanoparticle Biomarker Tagging (NBT) is the ideal technology to fit with the UICC (Union for International Cancer Control) campaign, offering non-invasive detection of an array of diseases through a simple breath test.

At just a fraction of the cost of current methods, the NBT can identify diseases and viruses within minutes. With early and fast identification, cancer is more likely to respond to effective treatment and result in a greater probability of survival, less suffering, and often less expensive and less intensive treatment.

Cancer is a disease which occurs when changes in a group of normal cells within the body lead to uncontrolled, abnormal growth forming a lump called a tumour; this is true of all cancers except leukaemia (cancer of the blood). If left untreated, tumours can grow and spread into the surrounding normal tissue, or to other parts of the body via the bloodstream and lymphatic systems, and can affect the digestive, nervous and circulatory systems or release hormones that may affect body function.

NBT technology works for early detection of cancer by detecting “biomarkers” in a breath, which are DNA-protein controlled volatile organic compounds (VOCs) metabolites specific to diseases. These VOCs are the “fingerprints” of disease and NBT is far more sensitive than current screening methods. Whereas similar technology can require a concentration of thousands of biomarker molecules to detect the presence of a disease or virus, the NBT can detect concentrations as small as a single molecule.

“Ancon Medical’s NBT device is a much better alternative than CT scans early on and far cheaper too,” said Wesley Baker, CEO of ANCON Medical. “It can screen a wide range of at-risk individuals, allowing doctors to discover the presence of pathologies at an early state. For many, once cancer is diagnosed, it is too late. For example, with a lung cancer diagnosis, more than half die within one year. NBT has the potential to find lung cancer in its earliest stages, where more than 57 per cent has a five-year survival rate.”

For more information on World Cancer Day and to join the call-to-action, visit https://www.worldcancerday.org/.
Further information:

ANCON Medical NBT technology research: http://anconmedical.com/nbt-technology/.
ANCON Medical cancer detection: http://anconmedical.com/disease-screening/detection-of-cancer/.

Joanna Stephens
Ancon Technologies & Ancon Medical
+44 1227 811705
email us here


Source: EIN Presswire

Super Brush LLC Exhibiting at MD&M West 2019

Super Brush Logo

Super Brush LLC

Foam Cleaning Swabs

Wide-range of foam swabs

Visit Super Brush at MDM West 2019

Booth 1863 at MDM West 2019

Super Brush will be showcasing their swabs for device assembly operations, swabs for inclusion in medical kits and trays, and swabs for cleaning electronics.

The MD&M West show is a perfect opportunity to demonstrate the value a US manufacturer of innovative, precision cleaning products can provide.”

— Misty McGinnes, Super Brush’s General Manager

SPRINGFIELD, MA, USA, February 1, 2019 /EINPresswire.com/ — Building on Super Brush’s successful 2018 MD&M West show, the Super Brush team will return to Anaheim to meet with medical design and manufacturing attendees. Super Brush will be showcasing their swabs for device assembly operations, swabs for inclusion in medical kits and trays, and swabs for cleaning electronics and printers.

The MD&M West show will be on February 5-7th at the Anaheim Convention Center. There will be over 19,000 attendees and over 1,900 exhibitors. The Super Brush team will be located at booth 1863 to answer any questions about foam swab technology.

According to Misty McGinnes, Super Brush’s General Manager, “Face to face meetings with manufacturers and product developers are critical in the current, fast-paced, and ever-changing arena of global supply. Although Super Brush has been serving this industry for decades, the MD&M West show is a perfect opportunity to demonstrate the value a US manufacturer of innovative, precision cleaning products can provide.”

About Super Brush

Super Brush LLC specializes in the design, development, and manufacturing of foam swabs and applicators. From medical applicators to patented firearm cleaning swabs, Super Brush provides industries with technically advanced foam swabs. These swabs are perfect for cleaning equipment and delicate surfaces, removing excess materials, applying lubricants, solvents, and adhesives, and a host of other solutions. ISO 13485 certified FDA registered.

For more information contact media@superbrush.com.

Michael Lecrenski
Super Brush LLC
+1 413-572-4063
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

InSphero Organ-on-a-Chip Solutions Featured in SLAS Technology

Akura™ Flow Organ on a Chip

The Akura™ Flow Organ on a Chip interconnects InSphero 3D human tissue models in organ networks

InSphero Logo

InSphero Logo

Early proof-of-concept studies demonstrate versatility of scalable microfluidic platform for 3D microtissue-based, multi-organ models

Our technology provides researchers with a completely new tool for studying complex diseases and discovering new cures.””

— Olivier Frey, PhD, InSphero Head of Technology and Platforms

SCHLIEREN, ZURICH, SWITZERLAND, February 1, 2019 /EINPresswire.com/ — The February 2019 issue of the scientific journal SLAS Technology showcases the innovative, scalable microfluidic platform that inspired InSphero’s new organ-on-a-chip system: Akura™ Flow. InSphero Head of Technology and Platforms Dr. Olivier Frey and co-authors from Prof. Andreas Hierlemann’s bioengineering lab at ETH Zürich were invited to contribute the article for the journal as top finalists for the prestigious SLAS Innovation Award in 2018.

InSphero has been testing and perfecting organ-on-a-chip solutions since 2011, when the company teamed up with ETH, AstraZeneca and other leading academic groups in the EU-supported research project Body-on-a-Chip, that aimed to mimic the response of the human body as a whole to drugs for safety and efficacy testing. Working in collaboration, microfluidics experts at ETH Zürich and InSphero, were able to refine early prototypes of the system and create the basis for a higher order system suitable for applications such as low clearance assays and metabolic disease modeling. InSphero has since been working on commercialization of the Akura™ Flow system to ensure the operational robustness and trustworthy results demanded by the pharmaceutical industry. Akura™ Flow is also the first technology to addresses important industry needs, such as short setup times of one week and the capability to automatically extract 3D microtissues from the device for downstream next-gen sequencing, histology or other rich endpoints.

Dr. Frey, who spearheads Akura™ Flow product development, says, “This is truly an exciting time to be working in the field of biomedical microfluidics. In partnership with our customers, we can now develop a wide range of multi-tissue configurations, from tumor-liver-immune system interactions for cancer research to liver-pancreatic islet communications for the study of metabolic diseases, such as diabetes and NASH. Our technology provides researchers with a completely new tool for studying complex diseases and discovering new cures.”

InSphero will be presenting on Akura™ Flow and 3D human tissue models for drug discovery and development at SLAS2019, Feb 2-6, in Washington, DC. The company will also be participating in the SLAS Exhibition and can be found at booth 848.

To read the SLAS Technology paper, “Scalable Microfluidic Platform for Flexible Configuration of and Experiments with Microtissue Multiorgan Models“, see: https://journals.sagepub.com/doi/abs/10.1177/2472630318802582?journalCode=jlad

To learn more about the Akura Flow organ-on-a-chip system, visit: https://insphero.com/science/enabling-technology/microphysiological-systems/

For more information about InSphero, visit www.insphero.com.

# # #

Frank Junker, Chief Business Officer
InSphero AG
+41 44 515 04 90
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

8 Videos Provide a Quick Way to Understand the Role of Germs in Alzheimer’s Disease

These eight one-minute videos reveal clues germs play a role in Alzheimer's disease.

Historically, research has proven many illnesses are linked to germs including polio, ulcers and malaria.”

— Dr. Leslie Norins

NAPLES, FL, UNITED STATES, February 1, 2019 /EINPresswire.com/ — A set of eight one-minute videos released by Alzheimer’s Germ Quest, Inc. answers basic questions about the possibility Alzheimer’s disease might be triggered by an infectious agent.

Video topics include microbes in the brain, the role of plaques and inflammation, possible evidence of transmittal, infections that can take years to surface (e.g., herpes zoster after childhood chickenpox) and possible beneficial effects of antibiotics.

“Historically, research has proven many illnesses not initially suspected of being infectious are linked to germs including polio, ulcers and malaria,” said Dr. Leslie Norins, Alzheimer’s Germ Quest, Inc. CEO.

The videos can be viewed at www.alzgerm.org/videos or on YouTube.

Alzheimer’s Germ Quest, Inc. is a public benefit corporation headquartered in Naples, Florida. It advocates for more research into the potential infectious nature of Alzheimer’s and is also the sponsor of the $1 Million Alzheimer’s Germ Quest Challenge Award for scientists.

Mollie Page
Alzheimer's Germ Quest, Inc.
+1 2397777243
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Could Alzheimer’s Be Transmitted to Caretakers?


Source: EIN Presswire